文档视界 最新最全的文档下载
当前位置:文档视界 › 虫草素作用机制 - Medchemexpress - MCE中国

虫草素作用机制 - Medchemexpress - MCE中国

Cordycepin

10% DMSO 40% PEG300 5% Tween-80 45% saline

10% DMSO 90% (20% SBE-β-CD in saline)

以 1 mL ?作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD ?理盐??溶液中,混合

均匀。

请依序添加每种溶剂: 10% DMSO 90% corn oil

3.

Solubility: ≥ 2.5 mg/mL (9.95 mM); Clear solution

此?案可获得 ≥ 2.5 mg/mL (9.95 mM,饱和度未知) 的澄清溶液,此?案不适?于实验周期在半个?以上的实验。

以 1 mL ?作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL ??油中,混合均匀。

BIOLOGICAL ACTIVITY

?物活性Cordycepin (3'-Deoxyadenosine) 是从冬?夏草中分离的?种核苷衍?物,在类风湿性关节炎滑膜成纤维细胞 (RASF) 中,抑制 IL-1β 诱导的 MMP-1 和 MMP-3 表达,这种作?存在剂量依赖性。Cordycepin 通过抑制细菌的腺苷激酶杀死

结核分枝杆菌。

IC?? & Target MMP-1MMP-3

体外研究Cordycepin is a potent inhibitor of IL-1β-induced chemokine production and MMP expression and strongly blocks the p38/JNK/AP-1 signalling pathway in RASFs. The effect of Cordycepin on cellular toxicity of RASFs is assessed using

MTT assay. Treatment of RASFs with Cordycepin (50 μM or 100 μM) for 24 h does not cause any significant change in

cell viability. However, cell viability is slightly decreased when cells are incubated with 100 μM Cordycepin for 48 h[1].

PROTOCOL

Cell Assay [1]RASFs (2×104 cells/well) are treated with various concentrations of Cordycepin (50 μM or 100 μM). After incubation for 1 h, 12 h and 24 h, cells are washed twice with PBS, MTT (0.5 mg/mL PBS) is added to each well and incubated at

37°C for 30 min. Formazan crystals formed are dissolved by adding DMSO (100 μL/well) and the absorbance is read at

570 nm using a microplate reader[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

客户使?本产品发表的科研?献

? Nat Commun. 2019 Jun 10;10(1):25

See more customer validations on https://www.docsj.com/doc/7b8909484.html,

REFERENCES

[1]. Noh EM, et al. Cordycepin inhibits IL-1beta-induced MMP-1 and MMP-3 expression in rheumatoid arthritis synovial fibroblasts. Rheumatology (Oxford). 2009 Jan;48(1):45-8.

[2]. Huang F, et al. Cordycepin kills Mycobacterium tuberculosis through hijacking the bacterial adenosine kinase. PLoS One. 2019 Jun 14;14(6):e0218449. McePdfHeight

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 400-820-3792; 021-******** Fax: 021-******** E-mail: tech@https://www.docsj.com/doc/7b8909484.html,

Master of Small Molecules — 您?边的抑制剂?师

相关文档